Anti-human Paraoxonase-1 Antibody
PON-2-8Gb, Biotin

ORDERING INFORMATION

Catalog Number: BML048

Lot Number:

Size: 50 μg

Formulation: 0.2 μm filtered PBS solution

Storage: -80˚C

Specificity: human paraoxonase-1

Immunogen: paraoxonase-1 purified from pooled plasma

Ig Type: IgG2b

Application: Western blot

Sandwich ELISA

Preparation
Produced in mice immunized with paraoxonase-1 (PON-1) purified from human plasma. PON-1 specific IgG was purified from mouse ascites fluid with a protein A-Sepharose.

Formulation
0.2 μm filtered PBS solution

Storage
IgG in PBS solution are stable for twelve months from the date of receipt when stored at -80˚C. Avoid repeated freeze-thaw cycles.

Specificity
This antibody has been selected for its ability to bind for human paraoxonase-1 (1).

Additional Applications
Western Blot – Thai antibody can be used at 0.5 – 1.0 μg/mL with the appropriate secondary reagent to detect human plasma PON-1. The detection limit for purified PON-1 and plasma sample is approximately 0.01 μg/lane and 0.05 μL, respectively, under non-reducing and reducing conditions.

Sandwich ELISA – This antibody can be used as a capture antibody in a human PON-1 ELISA in combination with the monoclonal detection antibody (Catalog #PO4C1b). A general protocol is provided on the next page. Using plates coated with 100 μL/well of the capture antibody, in combination with 100 μL/well of the detection antibody at 500 ng/mL, an ELISA for sample volumes of 100 μL can be obtained. Titrate each preparation of the serum sample for standard preparation to arrive at the most suitable dose range. For this antibody pair, a two-fold dilution series starting at 600 pg/mL is suggested. For more information, please see the next page or the reference (1).

Optimal dilutions should be determined by each laboratory for each application.

References

(1) Kujiraoka et al., A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res, 2000;41:1358-1363.

(2) van Himbergen et al., Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res, 2005;46:445-451.

(3) Kujiraoka et al., Effects of intravenous apolipoprotein A-I/phosphatidylcholine discs on paraoxonase and platelet-activating factor acetylhydrolase in human plasma and tissue fluid. Atherosclerosis, 2004;176:57-62.

(4) Noto et al, Exclusive association of paraoxonase 1 with high-density lipoprotein particles in apolipoprotein A-I deficiency. Biochem Biophys Res Commun, 2001;289:395-401.

FOR RESEARCH USE ONLY. NOT FOR USE IN HUMANS.

BML, Inc.

1361-1 Matoba, Kawagoe, Saitama 350-1101, Japan

TEL +81-49-232-0440/FAX +81-49-232-5480

5/1/06